A systems biological approach to identify key transcription factors and their genomic neighborhoods in human sarcomas

Chinese Journal of Cancer

Volumn 30, Issue 1, 2011, Pages 27-40

  Ylipää, Antti ^a   Yli Harja, Olli ^a   Zhang, Wei ^a,b   Nykter, Matti ^a  

^a TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Binding motif; Gene regulation; Sarcoma; Systems biology; Transcription factor

Indexed keywords

COILED COIL DOMAIN CONTAINING 6 PROTEIN; LYMPHOID ENHANCER FACTOR 1; MEMBRANE PROTEIN; MYC PROTEIN; SERUM RESPONSE FACTOR; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR MAF; TRANSCRIPTION FACTOR NKX2.5; TRIPARTITE MOTIF CONTAINING 63 PROTEIN; UNCLASSIFIED DRUG; VITAMIN D RECEPTOR; ZINC FINGER PROTEIN; ZINC FINGER PROTEIN 350;

ARTICLE; CANCER CLASSIFICATION; CANCER TISSUE; CONTROLLED STUDY; GASTROINTESTINAL STROMAL TUMOR; GENE EXPRESSION PROFILING; GENE REGULATORY NETWORK; GENETIC REGULATION; HUMAN; HUMAN TISSUE; LEIOMYOSARCOMA; MAJOR CLINICAL STUDY; PROTEIN ANALYSIS; PROTEIN FUNCTION; SEQUENCE ALIGNMENT; SIGNAL TRANSDUCTION; SYSTEMS BIOLOGY;

EID: 79954551932     PISSN: 1000467X     EISSN: 1944446X     Source Type: Journal    
DOI: 10.5732/cjc.010.10541     Document Type: Article

References (64)

1. Knudson AG. Cancer genetics [J]. Am J Med Genet, 2002,111(1):96-102.
2. Baylin SB, Herman JG. DNA hypermethylation in tumorigenesis: epigenetics joins genetics [J]. Trends Genet, 2000,16(4):168-174.
3. Baylin SB, Esteller M, Rountree MR, et al. Aberrant patterns of DNA methylatlon, chromatin formation and gene expression in cancer [J]. Hum Mol Genet, 2001,10(7):687-692.
4. Bond GL, Hu W, Levlne A. A single nucleotide polymorphism In the MDM2 gene: from a molecular and cellular explanation to clinical effect [J]. Cancer Res, 2005,65(13):5481-5484.
5. Beer DG, Kardla SL, Huang CC, et al. Gene-expression profiles predict survival of patients with lung adenocarcinoma [J]. Nat Med, 2002,8(8):816-824.
6. Bhattacharjee A, Richards WG, Staunton J, et al. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses [J]. Proc Nati Acad Sei USA, 2001,98(24):13790-13795.
7. Camós M, Esteve J, Jares P, et al. Gene expression profiling of acute myeloid leukemia with translocation t (8;16)(p11;p13) and MYST3-CREBBP rearrangement reveals a distinctive signature with a specific pattern of HOX gene expression [J].Cancer Res, 2006,66(14):6947-6954.
8. Chang HY, Nuyten DS, Sneddon JB, et al. Robustness, scalability, and Integration of a wound-response gene expression signature In predicting breast cancer survival [J]. Proc Nati Acad Sei USA, 2005,102(10):3738-3743.
9. Huang F, Reeves K, Han X, et al. Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatlnib: rationale for patient selection [J]. Cancer Res, 2007,67(5):2226-2238.
10. Kim S, Dougherty ER, Shmulevlch I, et al. Finding strong gene sets for classification of gliomas [J]. Mol Cancer Ther, 2002,1: 1229-1236.
11. Kobayashi T, Yamaguchi M, Kim S, et al. Microarray reveals differences In both tumors and vascular specific gene expression In de novo CD5 * and CD5 diffuse large B-cell lymphomas [J]. Cancer Res, 2003,63(1):60-66.
12. llzuka N, Oka M, Yamada-Okabe H, et al. Ollgonucleotlde microarray for prediction of early ¡ntrahepatlc recurrence of hepatocellular carcinoma after curative resection [J]. Lancet, 2003,361 (9361):923-929.
13. Pomeroy SL, Tamayo P, Gaasenbeek M, et al. Prediction of central nervous system embryonal tumour outcome based on gene expression [J]. Nature, 2002,415(6870):436-442.
14. Ramaswamy S, Ross KN, Lander ES, et al. A molecular signature of metastasis In primary solid tumors [J]. Nat Genet, 2003,33(1):49-54.
15. Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma [J]. N Engl J Med, 2002,346(25):1937-1947.
16. van't Veer LJ, Dal H, van de Vljver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer [J]. Nature, 2002,415(6871):530-536.
17. van de Vljver MJ, He YD, van't Veer LJ, et al. A gene-expression signature as a predictor of survival In breast cancer [J]. N Engl J Med, 2002,347(25): 1999-2009.
18. Wang Y, Klijn JG, Zhang Y, et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer [J]. Lancet, 2005,365(9460):671-679.
19. Yeoh EJ, Ross ME, Shurtleff SA, et al. Classification, subtype discovery, and prediction of outcome In pédiatrie acute lymphoblastlc leukemia by gene expression profiling [J]. Cancer Cell, 2002,1(2):133-143.
20. Ambrolse C, McLachlan GJ. Selection bias In gene extraction on the basis of microarray gene-expression data [J]. Proc Nati Acad Sei USA, 2002,99(10):6562-6566.
21. Garber K. Genomlc medicine. Gene expression tests foretell breast cancer's future [J]. Science, 2004,303 (5665):1754-1755.
22. Mlchlels S, Kosclelny S, Hill C. Prediction of cancer outcome with mlcroarrays: a multiple random validation strategy [J]. Lancet, 2005,365(9458):488-492
23. Miller LD, Long PM, Wong L, et al. Optimal gene expression analysis by mlcroarrays [J]. Cancer Cell, 2002,2(5):353-361.
24. Simon R. Diagnostic and prognostic prediction using gene expression profiles In high-dlmenslonal microarray data [J]. Br J Cancer, 2003,89(9):1599-1604.
25. Wessels LFA, Relnders MJT, Hart AAM, et al. A protocol for building and evaluating predictors of disease state based on microarray data [J]. Blolnformatlcs, 2005,21 (19):3755-3762.
26. Carro MS, Llm WK, Alvarez MJ, et al. The transcrlptlonal network for mesenchymal transformation of brain tumours [J]. Nature, 2010,464(7279):318-325.
27. Huang E, Ishlda S, Plttman J, et al. Gene expression phenotyplc models that predict the activity of oncogenlc pathways [J]. Nat Genet, 2003,34(2):226-230.
28. Lamb J, Ramaswamy S, Ford HL, et al. A mechanism of cyclln D1 action encoded In the patterns of gene expression In human cancer [J]. Cell, 2003,114(3):323-324.
29. Mootha VK, Llndgren CM, Eriksson KF, et al. PGC-1alpha- responslve genes Involved In oxldatlve phosphorylatlon are coordlnately downregulared In human diabetes [J]. Nat Genet, 2003,34(3):267-274.
30. Rhodes DR, Yu J, Shanker K, et al. Large-scale meta-analysls of cancer microarray data Identifies common transcrlptlonal profiles of neoplastlc transformation and progression [J]. Proc Nati Acad Scl USA, 2004,101(25):9309-9314.
31. Segal E, Friedman N, Koller D, et al. A module map showing conditional activity of expression modules In cancer [J]. Nat Genet, 2004,36(10):1090-1098.
32. Segal E, Friedman N, Kamlnskl N, et al. From signatures to models: understanding cancer using mlcroarrays [J]. Nat Genet, 2005,37(Suppl):S38-S45.
33. The Gene Ontology Consortium. Gene ontology: tool for the unification of biology [J]. Nat Genet, 2000,25(1):25-29.
34. Kanehlsa M, Goto S. KEGG: Kyoto Encyclopedia of Genes and Genomes [J]. Nucleic Adds Res, 2000,28(1):27-30.
35. Pathway Commons database [http://www.pathwaycommons.org/pc/].
36. Vogelsteln B, Klnzler K. Cancer genes and the pathways they control [J]. Nat Med, 2004,10(8):789-799.
37. Stfrlle T, Pérou CM, Tlbshlranl R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical Implications [J]. Proc Nati Acad Scl USA, 2001,98(19):10869-10874.
38. Verhaak RG, Hoadley KA, Purdom E, et al. Integrated genomlc analysis Identifies clinically relevant subtypes of glloblastoma characterized by abnormalities In PDGFRA, IDH1, EGFR, and NF1 [J]. Cancer Cell, 2010,17(1):98-110.
39. Dunlap SM, Celestino J, Wang H, et al. Insulln-IIke growth factor binding protein 2 promotes glloma development and progression [J]. Proc Nati Acad Scl USA, 2007,104(28): 11736-11741.
40. Demetrl G, Benjamin R, Blanke C, et al. NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST) - update of the NCCN clinical practice guidelines [J]. J Nati Compr Cane Netw, 2007,5(Suppl 2):S1-S29.
41. Joensuu H. Gastrointestinal stromal tumor (GIST) [J]. Ann Oncol, 2006,17(Suppl 10):280-286.
42. Katz S, DeMatteo R. Gastrointestinal stromal tumors and lelomyosarcomas [J]. J Surg Oncol, 2008,97(4):350-359.
43. Heinrich M, Corless C, Duenslng A, et al. Pdgfra activating mutations In gastrointestinal stromal tumors [J]. Science, 2003,299(5607):708-710.
44. Trent JC, Lazar AJ, Zhang W. Molecular approaches to resolve diagnostic dilemmas: the case of gastrointestinal stromal tumor and lelomyosarcoma [J]. Future Oncol, 2007,3(6):629-637.
45. Price N, Trent J, El-Naggar A, et al. Highly accurate two-gene classifier for differentiating gastrointestinal stromal tumors and lelomyosarcomas [J]. Proc Nati Acad Scl USA, 2007,104(9): 3414-3419.
46. Yang D, Ylipää A, Yang J, et al. An Integrated study of aberrant gene copy number and gene expression In GIST and LMS [J]. Technol Cancer Res Treat, 2010,9(2):171-178.
47. Yllp ää A, Hunt K, Yang J, et al. Integratlve genomlc characterization and a genomlc staging system for gastrointestinal stromal tumors [J]. Cancer, 2010 Sep 3. [Epub ahead of print]
48. Hastie T, Tlbshlranl R, Friedman J. The elements of statistical learning: data mining Inference, and prediction [M]. Second edition. Springer-Verlag, 2008:763.
49. Storey J. A direct approach to false discovery rates [J]. Journal of the Royal Statistical Society, Serles B (Methodological), 2002,64(3):479-498.
50. Thljs G, Moreau Y, deSmet F, et al. INCLUSIve: Integrated clustering, upstream sequence retrieval and motif sampling [J]. Blolnformatlcs, 2002,18(2):331-332.
51. Nykter M, Lähdesmäkl H, Rust A, et al. A data Integration framework for prediction of transcription factor targets: a BCL6 case study [J]. Ann N Y Acad Scl, 2009,1558:205-214.
52. Valouev A, Johnson DS, Sundqulst A, et al. Genome-wide analysis of transcription factor binding sites based on ChlP-Seq data [J]. Nat Methods, 2008,5(9):829-834.
53. Langmead B, Trapnell C, Pop M, et al. Ultrafast and memory-efficient alignment of short DNA sequences to the human genome [J]. Genome Biol, 2009,10(3):R25.
54. Zhang Y, Liu T, Meyer CA, et al. Model-based analysis of ChlP-Seq (MACS) [J]. Genome Biol, 2008,9(9):R13.
55. Cooper SJ, Trlnkleln ND, Nguyen L, et al. Serum response factor binding sites differ In three human cell types [J]. Genome Res, 2007,17(2):136-144.
56. Perot G, Derré J, Colndre JM, et al. Strong smooth muscle differentiation Is dependent on myocardln gene amplification In most human retroperltoneal lelomyosarcomas [J]. Cancer Res, 2009,69(6):2269-2278.
57. Labbe E, Letamendla A, Attlsano L. Association of Smads with lymphold enhancer binding factor 1/T cell-specific factor mediates cooperative signaling by the transforming growth factor-ß and Wnt pathways [J]. Proc Nati Acad Sei USA, 2000,97(15):8358-8363.
58. Gandhlrajan RK, Stalb PA, Mlnke K, et al. Small molecule Inhibitors of Wnt/ß-Catenln/Lef-1 signaling Induces apoptosls In chronic lymphocytlc leukemia cells In vitro and In vivo [J]. Neoplasla, 2010,12(4):326-335.
59. Celettl A, Cerrato A, Merolla F, et al. H4 (D10S170), a gene frequently rearranged with RET In papillary thyroid carcinomas: functional characterization [J]. Oncogene, 2004,23(1):109-121.
60. Oster SK, Ho CS, Soucie EL, et al. The myc oncogene: MarvelouslY Complex [J]. Adv Cancer Res, 2002,84 81-154.
61. Wang Z, Wang DZ, Pipes GC, et al. Myocardln is a master regulator of smooth muscle gene expression [J]. Proc Nati Acad Scl USA, 2003,100(12):7129-7134.
62. Phlllppar U, Schratt G, Dieterich C, et al. The SRF target gene Fhl2 antagonizes RhoA/MAL-dependent activation of SRF [J]. Mol Cell, 2004,16(6):867-880.
63. Cen B, Selvaraj A, Prywes R. Myocardln/MKL family of SRF coactlvators: key regulators of Immediate early and muscle specific gene expression [J]. J Cell Blochem, 2004,93(1):74-82.
64. Mlettlnen M, Lasota J. Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis [J]. Arch Pathol Lab Med 2006,130(10):1466-1478.